



## Enterome to Present Immunotherapy Pipeline Updates at Upcoming Investor Meetings

Paris, France – November 5<sup>th</sup>, 2024

**Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform**, today announced that Pierre Bélichard, CEO, and Christelle Dumoussaud, CFO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following events:

- **Inv€\$tival Showcase in London, UK, November 18, 2024**
  - Enterome's presentation is scheduled at 13:30 GMT on the "Biotech Late Growth" stage.
- **Jefferies' London Healthcare Conference, UK, November 19-21, 2024**
- **43<sup>rd</sup> J.P. Morgan Annual Healthcare Conference in San Francisco, USA, January 13-16, 2025**

Enterome's management team will also attend the 66<sup>th</sup> **American Society of Hematology (ASH) Annual Meeting and Conference**, from **December 7-10, 2024, in San Diego, California**, and will be available to discuss the latest clinical advances from the company's onco-hematology pipeline.

### Contacts

ENTEROME	MEDIA RELATIONS
<b>Marie-Laure Bouttier</b> <b>Chief Corporate Officer</b> +33 (0)1 76 21 58 15 <a href="mailto:communication@enterome.com">communication@enterome.com</a>	<b>Vigo Consulting</b> Melanie Toyne-Sewell / Rozi Morris +44 207 390 0237 / 0231 <a href="mailto:enterome@vigoconsulting.com">enterome@vigoconsulting.com</a>

### About Enterome

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome's pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.

Enterome's first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens.



The company's oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies:

- EO2463, currently in the Phase 2 'SIDNEY' clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy;
- EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 'ROSALIE' study;
- EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 'AUDREY' study.

Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships.

For more information, please visit the company's website at: [www.enterome.com](http://www.enterome.com)